Abstract
Best macular dystrophy (BMD) is an autosomal dominant macular dystrophy of childhood onset characterized by bilateral and symmetric vitelliform lesions. Several stages of disease have been well-described in the literature. Choroidal neovascularization (CNV) has traditionally been considered a hallmark of end-stage disease, and anti-vascular endothelial growth factor (anti-VEGF) agents have been used to improve visual prognosis. While CNV was historically detected with fluorescein angiography, optical coherence tomography angiography (OCTA) has recently been employed as a novel mechanism for identifying CNV in BMD. In this case series, we discuss our institutional experience with using OCTA to detect CNV in BMD and contextualize this experience within the broader emerging literature. While OCTA allows for the identification of CNV in less severe stages of BMD, the management of this CNV remains uncertain.
Original language | English (US) |
---|---|
Article number | 213 |
Pages (from-to) | 1-6 |
Number of pages | 6 |
Journal | Medicina (Lithuania) |
Volume | 57 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2021 |
Keywords
- Anti-VEGF
- Best disease
- Best macular dystrophy
- Choroidal neovascularization
- Heredi-tary retinal dystrophies
ASJC Scopus subject areas
- General Medicine